188 related articles for article (PubMed ID: 29396966)
1. Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment.
Karaglani M; Ragia G; Panagopoulou M; Balgkouranidou I; Nena E; Kolios G; Papanas N; Manolopoulos VG; Chatzaki E
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):226-233. PubMed ID: 29396966
[TBL] [Abstract][Full Text] [Related]
2. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
Ragia G; Tavridou A; Petridis I; Manolopoulos VG
Diabetes Res Clin Pract; 2012 Oct; 98(1):119-24. PubMed ID: 22591706
[TBL] [Abstract][Full Text] [Related]
3. KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.
Song J; Yang Y; Mauvais-Jarvis F; Wang YP; Niu T
BMC Med Genet; 2017 Jun; 18(1):64. PubMed ID: 28587604
[TBL] [Abstract][Full Text] [Related]
4. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
Holstein A; Hahn M; Stumvoll M; Kovacs P
Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
[TBL] [Abstract][Full Text] [Related]
5. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.
Javorsky M; Klimcakova L; Schroner Z; Zidzik J; Babjakova E; Fabianova M; Kozarova M; Tkacova R; Salagovic J; Tkac I
Eur J Intern Med; 2012 Apr; 23(3):245-9. PubMed ID: 22385882
[TBL] [Abstract][Full Text] [Related]
6. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
Sato R; Watanabe H; Genma R; Takeuchi M; Maekawa M; Nakamura H
Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
[TBL] [Abstract][Full Text] [Related]
7. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
Sesti G; Laratta E; Cardellini M; Andreozzi F; Del Guerra S; Irace C; Gnasso A; Grupillo M; Lauro R; Hribal ML; Perticone F; Marchetti P
J Clin Endocrinol Metab; 2006 Jun; 91(6):2334-9. PubMed ID: 16595597
[TBL] [Abstract][Full Text] [Related]
8. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes.
Gloyn AL; Weedon MN; Owen KR; Turner MJ; Knight BA; Hitman G; Walker M; Levy JC; Sampson M; Halford S; McCarthy MI; Hattersley AT; Frayling TM
Diabetes; 2003 Feb; 52(2):568-72. PubMed ID: 12540637
[TBL] [Abstract][Full Text] [Related]
9. An analysis of the relationship between ABCC8 and KCNJ11 gene polymorphisms and diabetic retinopathy in Turkish population.
Alp E; Doguizi S; Mutlu Icduygu F; Akgun E; Sekeroglu MA; Ozer MA
Ophthalmic Genet; 2024 Apr; 45(2):126-132. PubMed ID: 38411150
[TBL] [Abstract][Full Text] [Related]
10. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.
Florez JC; Jablonski KA; Kahn SE; Franks PW; Dabelea D; Hamman RF; Knowler WC; Nathan DM; Altshuler D
Diabetes; 2007 Feb; 56(2):531-6. PubMed ID: 17259403
[TBL] [Abstract][Full Text] [Related]
11. KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients.
Li Q; Chen M; Zhang R; Jiang F; Wang J; Zhou J; Bao Y; Hu C; Jia W
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):748-54. PubMed ID: 25115353
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.
Klen J; Dolžan V; Janež A
Eur J Clin Pharmacol; 2014 Apr; 70(4):421-8. PubMed ID: 24442125
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study.
Loganadan NK; Huri HZ; Vethakkan SR; Hussein Z
Pharmacogenomics; 2021 Nov; 22(16):1057-1068. PubMed ID: 34665019
[No Abstract] [Full Text] [Related]
14. Replication of KCNJ11 (p.E23K) and ABCC8 (p.S1369A) Association in Russian Diabetes Mellitus 2 Type Cohort and Meta-Analysis.
Sokolova EA; Bondar IA; Shabelnikova OY; Pyankova OV; Filipenko ML
PLoS One; 2015; 10(5):e0124662. PubMed ID: 25955821
[TBL] [Abstract][Full Text] [Related]
15. ATP-dependent potassium channels and type 2 diabetes mellitus.
Bonfanti DH; Alcazar LP; Arakaki PA; Martins LT; Agustini BC; de Moraes Rego FG; Frigeri HR
Clin Biochem; 2015 May; 48(7-8):476-82. PubMed ID: 25583094
[TBL] [Abstract][Full Text] [Related]
16. Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses.
van Dam RM; Hoebee B; Seidell JC; Schaap MM; de Bruin TW; Feskens EJ
Diabet Med; 2005 May; 22(5):590-8. PubMed ID: 15842514
[TBL] [Abstract][Full Text] [Related]
17. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
[TBL] [Abstract][Full Text] [Related]
18. Effects of single nucleotide polymorphisms in K(ATP) channel genes on type 2 diabetes in a Turkish population.
Gonen MS; Arikoglu H; Erkoc Kaya D; Ozdemir H; Ipekci SH; Arslan A; Kayis SA; Gogebakan B
Arch Med Res; 2012 May; 43(4):317-23. PubMed ID: 22704848
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenetics of insulin secretagogue antidiabetics].
Winkler G; Gerô L
Orv Hetil; 2011 Oct; 152(41):1651-60. PubMed ID: 21959939
[TBL] [Abstract][Full Text] [Related]
20. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes.
Holstein JD; Kovacs P; Patzer O; Stumvoll M; Holstein A
Pharmacogenomics; 2012 Jan; 13(1):5-7; author reply 9-10. PubMed ID: 22176616
[No Abstract] [Full Text] [Related]
[Next] [New Search]
